Journal of Pain and Symptom Management
Volume 36, Issue 5 , Pages e5-e6 , November 2008

Midazolam-Induced Extrapyramidal Side Effects

References 

  1. Brown DJF, McArthur D, Moulsdale H. Subcutaneous midazolam as a cause of extrapyramidal side effects in a patient with prostate cancer. J Pain Symptom Manage. 2007;34(2):111–113
  2. Khan RB, Schmidt JE, Tamburro RF. A reversible generalized movement disorder in critically ill children with cancer. Neurocrit Care. 2005;3(2):146–149
  3. Vorsanger GJ, Roberts JT. Midazolam-induced athetoid movements of the lower extremities during epidural anesthesia reversed by physostigmine. J Clin Anesth. 1993;5(6):494–496
  4. Alfa JA, Bamgbade OA. Acute myoclonus following spinal anaesthesia. Eur J Anaesthesiol. 2008;25(3):256–257
  5. Davis DP, Hamilton RS, Webster TH. Reversal of midazolam-induced laryngospasm with flumazenil. Ann Emerg Med. 1998;32(2):263–265
  6. Weinbroum AA, Szold O, Ogorek D, Flaishon R. The midazolam-induced paradox phenomenon is reversible by flumazenil. Epidemiology, patient characteristics and review of the literature. Eur J Anaesthesiol. 2001;18(12):789–797
  7. Mohler H. GABA(A) receptor diversity and pharmacology. Cell Tissue Res. 2006;326(2):505–516
  8. Fritschy JM, Mohler H. GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J Comp Neurol. 1995;359(1):154–194
  9. Ondo WG, Hunter C. Flumazenil, a GABA antagonist, may improve features of Parkinson's disease. Mov Disord. 2003;18(6):683–685
  10. Ondo WG, Silay YS. Intravenous flumazenil for Parkinson's disease: a single dose, double blind, placebo controlled, cross-over trial. Mov Disord. 2006;21(10):1614–1617
  11. Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056: a novel ultra-short-acting Benzodiazepine. Anesthesiology. 2007;107(1):60–66

PII: S0885-3924(08)00437-5

doi: 10.1016/j.jpainsymman.2008.06.002

Journal of Pain and Symptom Management
Volume 36, Issue 5 , Pages e5-e6 , November 2008

Article Tools